Definium Therapeutics (NASDAQ:DFTX) Receives Outperform Rating from Royal Bank Of Canada

Definium Therapeutics (NASDAQ:DFTX)‘s stock had its “outperform” rating restated by Royal Bank Of Canada in a report issued on Friday, Benzinga reports. They presently have a $66.00 price objective on the stock. Royal Bank Of Canada’s price target indicates a potential upside of 70.98% from the company’s current price.

Several other equities research analysts have also recently weighed in on DFTX. Canaccord Genuity Group set a $64.00 price target on shares of Definium Therapeutics and gave the company a “buy” rating in a research report on Thursday, August 13th. JonesTrading increased their target price on shares of Definium Therapeutics from $74.00 to $90.00 and gave the stock a “buy” rating in a report on Thursday, August 13th. Stifel Nicolaus raised their target price on Definium Therapeutics from $30.00 to $60.00 and gave the stock a “buy” rating in a research note on Wednesday, July 8th. Citigroup reissued a “buy” rating on shares of Definium Therapeutics in a research note on Monday, June 22nd. Finally, Needham & Company LLC upped their price target on Definium Therapeutics from $50.00 to $66.00 and gave the company a “buy” rating in a research report on Wednesday, August 12th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $63.00.

Definium Therapeutics Price Performance

Shares of Definium Therapeutics stock opened at $38.60 on Friday. The company has a debt-to-equity ratio of 0.04, a current ratio of 6.95 and a quick ratio of 6.95. The business’s 50 day simple moving average is $43.11 and its two-hundred day simple moving average is $30.17. The stock has a market capitalization of $5.19 billion, a P/E ratio of -11.25 and a beta of 2.23. Definium Therapeutics has a one year low of $8.77 and a one year high of $49.70.

Definium Therapeutics (NASDAQ:DFTX) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($1.44) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.89). Analysts forecast that Definium Therapeutics will post -3.02 EPS for the current year.

Insider Activity at Definium Therapeutics

In related news, CFO Brandi Roberts sold 3,013 shares of the business’s stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $45.03, for a total transaction of $135,675.39. Following the transaction, the chief financial officer owned 209,487 shares in the company, valued at $9,433,199.61. The trade was a 1.42% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Mark Sullivan sold 13,008 shares of the stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $45.03, for a total transaction of $585,750.24. Following the completion of the transaction, the insider directly owned 320,571 shares of the company’s stock, valued at approximately $14,435,312.13. The trade was a 3.90% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 67,119 shares of company stock valued at $2,887,496. 2.40% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Sequoia Financial Advisors LLC purchased a new position in shares of Definium Therapeutics in the 2nd quarter valued at approximately $812,000. WINTON GROUP Ltd bought a new stake in shares of Definium Therapeutics during the 2nd quarter valued at $240,000. Engineers Gate Manager LP bought a new stake in shares of Definium Therapeutics during the 2nd quarter valued at $481,000. Integrated Wealth Concepts LLC purchased a new stake in shares of Definium Therapeutics in the 2nd quarter worth about $159,000. Finally, NewEdge Advisors LLC purchased a new stake in shares of Definium Therapeutics in the 2nd quarter worth about $222,000. Institutional investors own 27.91% of the company’s stock.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.